keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer recurrence

keyword
https://www.readbyqxmd.com/read/29324926/risk-stratification-and-staging-in-prostate-cancer-with-prostatic-specific-membrane-antigen-pet-ctobjective-a-one-stop-shop
#1
Manoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Harish Chandra Goel, Amitabh Singh, Vineet Talwar, Saroj Kumar Sahoo
OBJECTIVE: Current imaging modalities for prostate cancer (PC) had limitations for risk stratification and staging. Magnetic resonance imaging (MRI) frequently underestimated lymphatic metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in diagnosing PC recurrence and staging. We hypothesized it can become one-stop-shop for initial risk stratification and staging...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29323532/identification-of-cdk2-as-a-novel-target-in-treatment-of-prostate-cancer
#2
Xifeng Yin, Jun Yu, Yang Zhou, Chengyue Wang, Zhimin Jiao, Zhounan Qian, Hao Sun, Binghai Chen
AIM: This study aims the potential gene involved in the metastasis of prostate cancer (Pca). METHODS: PubMed GEO datasets (GSE6605 and GSE6606) were downloaded. We used multiple bioinformatics methods to screen differentially expressed genes in Pca. Gene network was built by STRING and visualized by Cytoscape. All of the hub genes were analyzed by cBioPortal. Inhibition of CDK2 including siRNA, inhibitor and cas9-induced CDK2 knockout was followed by an invasion assay...
January 11, 2018: Future Oncology
https://www.readbyqxmd.com/read/29320570/image-guided-whole-pelvic-intensity-modulated-radiotherapy-for-biochemical-recurrence-following-radical-prostatectomy-in-high-risk-prostate-cancer-patients
#3
Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Choung-Soo Kim
BACKGROUND: The optimal field size of salvage radiotherapy (SRT) for biochemical recurrence, particularly for patients with high-risk prostate cancer, remains undefined. This retrospective analysis was performed to investigate oncological outcomes as well as treatment-related toxicity following salvage intensity-modulated radiotherapy (IMRT) to the whole pelvis and to compare the results with other studies implementing a small field size of the prostate bed. METHODS: The medical records of 170 patients with high-risk prostate cancer who received SRT for biochemical recurrence following prostatectomy were reviewed...
2018: PloS One
https://www.readbyqxmd.com/read/29320333/prostate-specific-membrane-antigen-pet-clinical-utility-in-prostate-cancer-normal-patterns-pearls-and-pitfalls
#4
Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging...
January 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29319919/outcomes-and-toxicities-in-intermediate-risk-prostate-cancer-patients-treated-with-brachytherapy-alone-or-brachytherapy-and-supplemental-external-beam-radiation-therapy
#5
Emily Schlussel Markovic, Michael Buckstein, Nelson N Stone, Richard G Stock
OBJECTIVE: To evaluate the cancer control outcomes and long-term treatment-related morbidity of brachytherapy as well as combination brachytherapy and EBRT in patients with intermediate-risk prostate cancer. MATERIALS AND METHODS: A retrospective review was conducted in a prospectively collected database of patients with intermediate-risk prostate cancer who were treated either with brachytherapy or brachytherapy and EBRT, with or without ADT, from 1990-2014. Urinary and erectile dysfunction symptoms are measured using the International Prostate Symptom Score (IPSS) and the Mount Sinai erectile function scale, and the Sexual Health Inventory for Men (SHIM), respectively...
January 10, 2018: BJU International
https://www.readbyqxmd.com/read/29317377/multiparametric-mri-for-the-detection-of-local-recurrence-of-prostate-cancer-in-the-setting-of-biochemical-recurrence-after-low-dose-rate-brachytherapy
#6
Luca F Valle, Matthew D Greer, Joanna H Shih, Tristan Barrett, Yan Mee Law, Andrew B Rosenkrantz, Haytham Shebel, Akhil Muthigi, Daniel Su, Maria J Merino, Bradford J Wood, Peter A Pinto, Andra V Krauze, Aradhana Kaushal, Peter L Choyke, Barış Türkbey, Deborah E Citrin
PURPOSE: Prostate multiparametric magnetic resonance imaging (mpMRI) has utility in detecting post-radiotherapy local recurrence. We conducted a multireader study to evaluate the diagnostic performance of mpMRI for local recurrence after low dose rate (LDR) brachytherapy. METHODS: A total of 19 patients with biochemical recurrence after LDR brachytherapy underwent 3T endorectal coil mpMRI with T2-weighted imaging, dynamic contrast-enhanced imaging (DCE) and diffusion-weighted imaging (DWI) with pathologic confirmation...
January 2018: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29315854/predictive-factors-of-biochemical-recurrence-after-radical-prostatectomy-for-high-risk-prostate-cancer
#7
Yukiko Murata, Katsunori Tatsugami, Masahiro Yoshikawa, Masumitsu Hamaguchi, Shigetomo Yamada, Yusuke Hayakawa, Kouhei Ueda, Seiya Momosaki, Naotaka Sakamoto
OBJECTIVE: To identify risk factors of biochemical recurrence after radical prostatectomy in high-risk patients. METHODS: A total of 191 high-risk prostate cancer patients according to the D'Amico classification treated with radical prostatectomy at a single institution between April 2000 and December 2013 were enrolled. The pathological evaluation including intraductal carcinoma of prostate was reassessed, and the clinical and pathological risk factors of biochemical recurrence were analyzed...
January 8, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29315388/galectin-3-and-cancer-stemness
#8
Pratima Nangia-Makker, Victor Hogan, Avraham Raz
Over the last few decades galectin-3, a carbohydrate binding protein, with affinity for N-acetyllactosamine residues, has been unique due to the regulatory roles it performs in processes associated with tumor progression and metastasis such as cell proliferation, homotypic/ heterotypic aggregation, dynamic cellular transformation, migration and invasion, survival and apoptosis. Structure-function association of galectin-3 reveals that it consists of a short amino terminal motif, which regulates its nuclear-cytoplasmic shuttling; a collagen α-like domain, susceptible to cleavage by matrix metalloproteases and prostate specific antigen (PSA); accountable for its oligomerization and lattice formation, and a carbohydrate recognition/binding domain containing the anti-death motif of the Bcl2 protein family...
January 5, 2018: Glycobiology
https://www.readbyqxmd.com/read/29314169/correlations-of-selenof-and-selenop-genotypes-with-serum-selenium-levels-and-prostate-cancer
#9
Dede N Ekoue, Emmanuel Ansong, Li Liu, Virgilia Macias, Ryan Deaton, Craig Lacher, Matthew Picklo, Larisa Nonn, Peter H Gann, Andre Kajdacsy-Balla, Gail S Prins, Vincent L Freeman, Alan M Diamond
BACKGROUND: Selenium status is inversely associated with the incidence of prostate cancer. However, supplementation trials have not indicated a benefit of selenium supplementation in reducing cancer risk. Polymorphisms in the gene encoding selenoprotein 15 (SELENOF) are associated with cancer incidence/mortality and present disproportionately in African Americans. Relationships among the genotype of selenoproteins implicated in increased cancer risk, selenium status, and race with prostate cancer were investigated...
January 5, 2018: Prostate
https://www.readbyqxmd.com/read/29312579/deletion-lengthening-at-chromosomes-6q-and-16q-targets-multiple-tumor-suppressor-genes-and-is-associated-with-an-increasingly-poor-prognosis-in-prostate-cancer
#10
Martina Kluth, Simon Jung, Omar Habib, Mina Eshagzaiy, Anna Heinl, Nina Amschler, Sawinee Masser, Malte Mader, Frederic Runte, Philipp Barow, Sohall Frogh, Jazan Omari, Christina Möller-Koop, Claudia Hube-Magg, Joachim Weischenfeldt, Jan Korbel, Stefan Steurer, Till Krech, Hartwig Huland, Markus Graefen, Sarah Minner, Guido Sauter, Thorsten Schlomm, Ronald Simon
Prostate cancer is characterized by recurrent deletions that can considerably vary in size. We hypothesized that large deletions develop from small deletions and that this "deletion lengthening" might have a "per se" carcinogenic role through a combinatorial effect of multiple down regulated genes. In vitro knockdown of 37 genes located inside the 6q12-q22 deletion region identified 4 genes with additive tumor suppressive effects, further supporting a role of the deletion size for cancer aggressiveness. Employing fluorescence in-situ hybridization analysis on prostate cancer tissue microarrays, we determined the deletion size at 6q and 16q in more than 3,000 tumors...
December 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29308527/psa-stratified-detection-rates-for-68ga-thp-psma-a-novel-probe-for-rapid-kit-based-68ga-labeling-and-pet-imaging-in-patients-with-biochemical-recurrence-after-primary-therapy-for-prostate-cancer
#11
Thorsten Derlin, Sebastian Schmuck, Cathleen Juhl, Johanna Zörgiebel, Sophie M Schneefeld, Almut C A Walte, Katja Hueper, Christoph A von Klot, Christoph Henkenberens, Hans Christiansen, James T Thackeray, Tobias L Ross, Frank M Bengel
PURPOSE: [68Ga]Tris(hydroxypyridinone)(THP)-PSMA is a novel radiopharmaceutical for one-step kit-based radiolabelling, based on direct chelation of 68Ga3+ at low concentration, room temperature and over a wide pH range, using direct elution from a 68Ge/68Ga-generator. We evaluated the clinical detection rates of [68Ga]THP-PSMA PET/CT in patients with biochemically recurrent prostate cancer after prostatectomy. METHODS: Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [68Ga]THP-PSMA PET/CT were analyzed retrospectively...
January 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29308088/distinct-subtypes-of-genomic-pten-deletion-size-influence-the-landscape-of-aneuploidy-and-outcome-in-prostate-cancer
#12
Thiago Vidotto, Daniel Guimarães Tiezzi, Jeremy A Squire
Background: Inactivation of the PTEN tumor suppressor gene by deletion occurs in 20-30% of prostate cancer tumors and loss strongly correlates with a worse outcome. PTEN loss of function not only leads to activation of the PI3K/AKT pathway, but is also thought to affect genome stability and increase levels of tumor aneuploidy. We performed an in silico integrative genomic and transcriptomic analysis of 491 TCGA prostate cancer tumors. These data were used to map the genomic sizes of PTEN gene deletions and to characterize levels of instability and patterns of aneuploidy acquisition...
2018: Molecular Cytogenetics
https://www.readbyqxmd.com/read/29307681/does-subclassification-of-pathologically-organ-confined-pt2-prostate-cancer-provide-prognostic-discrimination-of-outcomes-after-radical-prostatectomy
#13
Daniel P Nguyen, Emily A Vertosick, Vidit Sharma, Renato B Corradi, Antoni Vilaseca, Toshikazu Takeda, Daniel D Sjoberg, Nicole Benfante, Samson W Fine, Victor E Reuter, Peter T Scardino, James A Eastham, R Jeffrey Karnes, Karim A Touijer
PURPOSE: To test the latest update in the prostate cancer staging system by assessing prognostic association of pT2 subclassification with probabilities of survival-related outcomes in patients who underwent radical prostatectomy. PATIENTS AND METHODS: We retrospectively analyzed a total of 15,305 patients who underwent radical prostatectomy at two referral centers between 1985 and 2016 and had pT2 disease at final pathologic evaluation. Descriptive statistics compared baseline data stratified by pT2 substages (pT2a/b versus pT2c)...
January 4, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29306855/ureteral-intramural-metastatic-deposit-of-prostate-cancer-with-ureteric-obstruction
#14
Claire Pascoe, Todd G Manning, David Wetherell, Nathan Lawrentschuk
True metastatic ureteric lesions are exceptionally rare when sourced from any primary tumour. Primary prostatic cancer metastasis to the ureter is understandably even more atypical with very few cases reported in current literature. True intramural ureteric metastatic disease deposited from prostate cancer is an even rarer occurrence. We present a case of a man in his mid-60s with left-sided hydronephrosis in the setting of biochemical recurrence of Gleason 9 prostate cancer. Initially misdiagnosed as obstruction secondary to mass effect from a large trigonal lesion, subsequent investigation revealed solid intramural metastatic deposit of prostate primary tumour in the distal ureter...
January 6, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29306674/a-comparison-of-early-prostate-specific-antigen-decline-between-prostate-brachytherapy-and-different-fractionation-of-external-beam-radiation-impact-on-biochemical-failure
#15
Daniel Taussky, Stéphane Bedwani, Nissan Meissner, Jean-Paul Bahary, Carole Lambert, Maroie Barkati, Marie-Claude Beauchemin, Cynthia Ménard, Guila Delouya
PURPOSE: The aim of this study was to compare early prostate-specific antigen (PSA) decline patterns and PSA nadirs between low-dose-rate seed prostate brachytherapy (LDR-PB) and different fractionations of external beam radiotherapy (EBRT) and their predictive importance for biochemical failure (bF). METHODS AND MATERIALS: Patients with D'Amico low- or intermediate-risk prostate cancer who underwent a single-modality treatment without androgen deprivation were included in this study...
January 3, 2018: Brachytherapy
https://www.readbyqxmd.com/read/29305945/urosymphyseal-fistulas-resulting-from-endoscopic-treatment-of-radiation-induced-posterior-urethral-strictures
#16
Daniel D Shapiro, David C Goodspeed, Wade Bushman
Objective To describe the inciting events leading to urosymphyseal fistulas (UF) and pubic osteomyelitis (PO) in patients who had radiation induced urethral strictures. Materials and Methods We retrospectively reviewed patients who underwent simultaneous pubic debridement, simple cystectomy and urinary diversion for refractory UF and PO from 2014-2016. We investigated inciting events leading to UF as well as patient presenting symptoms, diagnosis, management, and outcomes. Results Five patients were identified over a two-year period...
January 3, 2018: Urology
https://www.readbyqxmd.com/read/29304991/a-multi-institutional-phase-2-trial-of-prostate-stereotactic-body-radiation-therapy-sbrt-using-continuous-real-time-evaluation-of-prostate-motion-with-patient-reported-quality-of-life
#17
William C Jackson, Robert T Dess, Dale W Litzenberg, Pin Li, Matthew Schipper, Seth A Rosenthal, Garrick C Chang, Eric M Horwitz, Robert A Price, Jeff M Michalski, Hiram A Gay, John T Wei, Mary Feng, Felix Y Feng, Howard M Sandler, Robert E Wallace, Daniel E Spratt, Daniel A Hamstra
PURPOSE: The use of stereotactic body radiation therapy (SBRT) for prostate cancer has been reported predominantly from single institutional studies, although concerns for broader adoption exist. METHODS AND MATERIALS: From 2011 through 2013, 66 men were accrued to a phase 2 trial at 5 centers. SBRT consisted of 5 fractions of 7.4 Gy to a total dose of 37 Gy using conventional linear accelerators. Electromagnetic transponders were used for motion management. Health-related quality of life (HRQOL) was evaluated via the Expanded Prostate Cancer Index Composite 26 questionnaire...
January 2018: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29304771/high-bcar1-expression-is-associated-with-early-psa-recurrence-in-erg-negative-prostate-cancer
#18
Asmus Heumann, Nina Heinemann, Claudia Hube-Magg, Dagmar S Lang, Katharina Grupp, Martina Kluth, Sarah Minner, Christina Möller-Koop, Markus Graefen, Hans Heinzer, Maria Christina Tsourlakis, Waldemar Wilczak, Corinna Wittmer, Frank Jacobsen, Hartwig Huland, Ronald Simon, Thorsten Schlomm, Guido Sauter, Stefan Steurer, Patrick Lebok, Andrea Hinsch
BACKGROUND: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression. METHODS: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion. RESULTS: BCAR1 staining was barely detectable in normal prostate glands but seen in 77...
January 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29303359/bayesian-penalised-likelihood-reconstruction-q-clear-of-18f-fluciclovine-pet-for-imaging-of-recurrent-prostate-cancer-semi-quantitative-and-clinical-evaluation
#19
Eugene J Teoh, Daniel R McGowan, David M Schuster, Maria Tsakok, Fergus V Gleeson, Kevin M Bradley
OBJECTIVE: 18F-Fluciclovine (FACBC) is an amino acid PET radiotracer approved for recurrent prostate cancer imaging. We investigate the use of Bayesian penalised likelihood (BPL) reconstruction for 18F-fluciclovine PET. METHODS: Fifteen 18F-fluciclovine scans were reconstructed using OSEM, OSEM+point spread function modeling (PSF) and BPL using β values 100-600. Lesion SUVmax, organ SUVmean and standard deviation were measured. De-identified reconstructions (OSEM, PSF, BPL using β200-600) from 10 cases were visually analysed by two readers who indicated their most and least preferred reconstructions, and scored overall image quality (IQ), noise level, background marrow IQ and lesion conspicuity...
January 5, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29301928/the-utility-of-pet-ct-in-external-radiation-therapy-planning-of-prostate-cancer
#20
Jeremie Calais, Minsong Cao, Nicholas G Nickols
Radiotherapy and radical prostatectomy are the definitive treatment options for patients with localized prostate cancer. A rising PSA after radical prostatectomy indicates prostate cancer recurrence, and these patients may still be cured with salvage radiotherapy. To maximize chance for cure, irradiated volumes should completely encompass the extent of disease. Therefore, accurate estimation of the location of disease is critical for radiotherapy planning in both the definitive and salvage settings. Conventional imaging for prostate cancer has limited sensitivity for detection of disease both at initial staging and at biochemical recurrence...
January 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
33996
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"